| scholarly article | Q13442814 |
| P356 | DOI | 10.1158/1535-7163.MCT-09-0295 |
| P698 | PubMed publication ID | 19671734 |
| P2093 | author name string | Frank E Jones | |
| Yun Zhu | |||
| Edi Brogi | |||
| Michael J Brumlik | |||
| Doyel Mitra | |||
| Samuel M Lesko | |||
| Jenny G Parvani | |||
| Tamika T Duplessis | |||
| Stella U Okamgba | |||
| P433 | issue | 8 | |
| P921 | main subject | trastuzumab | Q412616 |
| P304 | page(s) | 2152-2162 | |
| P577 | publication date | 2009-08-11 | |
| P1433 | published in | Molecular Cancer Therapeutics | Q2363144 |
| P1476 | title | An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance | |
| P478 | volume | 8 |
| Q35176075 | A class of genes in the HER2 regulon that is poised for transcription in breast cancer cell lines and expressed in human breast tumors |
| Q38824661 | Acquired Resistance to Clinical Cancer Therapy: A Twist in Physiological Signaling |
| Q59652245 | Alterations of the genes involved in the PI3K and estrogen-receptor pathways influence outcome in human epidermal growth factor receptor 2-positive and hormone receptor-positive breast cancer patients treated with trastuzumab-containing neoadjuvant c |
| Q38968877 | Alternative splicing and cell survival: from tissue homeostasis to disease |
| Q99582979 | Alternative splicing of HER2: a novel mediator of EGFR TKI resistance |
| Q52564290 | Alternative-splicing defects in cancer: Splicing regulators and their downstream targets, guiding the way to novel cancer therapeutics. |
| Q26797471 | Analysis of different HER-2 mutations in breast cancer progression and drug resistance |
| Q35237773 | Anti-Neoplastic Cytotoxicity of Gemcitabine-(C4-amide)-[anti-EGFR] in Dual-combination with Epirubicin-(C3-amide)-[anti-HER2/neu] against Chemotherapeutic-Resistant Mammary Adenocarcinoma (SKBr-3) and the Complementary Effect of Mebendazole |
| Q40678981 | Anti-Neoplastic Cytotoxicity of Gemcitabine-(C4-amide)-[anti-HER2/neu] in Combination with Griseofulvin against Chemotherapeutic-Resistant Mammary Adenocarcinoma (SKBr-3). |
| Q38068491 | Bringing cancer serological diagnosis to a new level: focusing on HER2, protein ectodomain shedding and neoepitope technology. |
| Q98726033 | Canonical ErbB-2 isoform and ErbB-2 variant c located in the nucleus drive triple negative breast cancer growth |
| Q37019041 | Clinical Significance of HER-2 Splice Variants in Breast Cancer Progression and Drug Resistance. |
| Q48195377 | Co-targeting the HER and IGF/insulin receptor axis in breast cancer, with triple targeting with endocrine therapy for hormone-sensitive disease |
| Q36107033 | Delivery of chemo-sensitizing siRNAs to HER2+-breast cancer cells using RNA aptamers |
| Q41595455 | Detection of recurrent alternative splicing switches in tumor samples reveals novel signatures of cancer |
| Q28829762 | Dexamethasone-(C21-phosphoramide)-[anti-EGFR]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency against pulmonary adenocarcinoma (A549) |
| Q34506613 | Downregulation of miR-342 is associated with tamoxifen resistant breast tumors. |
| Q33601653 | ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics |
| Q37977960 | Emerging role of microRNAs in drug-resistant breast cancer. |
| Q36311218 | Fludarabine- (C2-methylhydroxyphosphoramide)- [anti-IGF-1R]: Synthesis and Selectively "Targeted"Anti-Neoplastic Cytotoxicity against Pulmonary Adenocarcinoma (A549) |
| Q33578254 | Gemcitabine-(5'-phosphoramidate)-[anti-IGF-1R]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency in populations of pulmonary adenocarcinoma (A549) |
| Q40649082 | Gemcitabine-(C4-amide)-[anti-HER2/neu] Anti-Neoplastic Cytotoxicity in Dual Combination with Mebendazole against Chemotherapeutic-Resistant Mammary Adenocarcinoma. |
| Q41551956 | HER2 isoforms co-expression differently tunes mammary tumor phenotypes affecting onset, vasculature and therapeutic response |
| Q39389369 | Harnessing Integrative Omics to Facilitate Molecular Imaging of the Human Epidermal Growth Factor Receptor Family for Precision Medicine. |
| Q37666730 | Herceptin resistance database for understanding mechanism of resistance in breast cancer patients. |
| Q47131767 | How is Herstatin, a tumor suppressor splice variant of the oncogene HER2, regulated? |
| Q92947180 | Identification of New Mono/Dihydroxynaphthoquinone as Lead Agents That Inhibit the Growth of Refractive and Triple-Negative Breast Cancer Cell Lines |
| Q37889967 | Identifying responders to trastuzumab therapy in breast cancer |
| Q38850952 | In vitro and in vivo studies of the combination of IGF1R inhibitor figitumumab (CP-751,871) with HER2 inhibitors trastuzumab and neratinib |
| Q35892045 | Influence of Alternative Tubulin Inhibitors on the Potency of a Epirubicin-Immunochemotherapeutic Synthesized with an Ultra Violet Light-Activated Intermediate: Influence of incorporating an internal/integral disulfide bond structure and Alternative |
| Q56341979 | Intratumor lactate levels reflect HER2 addiction status in HER2-positive breast cancer |
| Q39143829 | Intrinsic HER2 V777L mutation mediates resistance to trastuzumab in a breast cancer patient. |
| Q36088788 | Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications |
| Q38979308 | Involvement of microRNAs in HER2 signaling and trastuzumab treatment. |
| Q55091931 | Lack of acquired resistance in HER2-positive breast cancer cells after long-term HER2 siRNA nanoparticle treatment. |
| Q26752780 | Mechanisms Behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome It |
| Q37671920 | Mechanisms of resistance to HER family targeting antibodies |
| Q36589865 | Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance. |
| Q34756694 | MicroRNA-7 inhibits multiple oncogenic pathways to suppress HER2Δ16 mediated breast tumorigenesis and reverse trastuzumab resistance |
| Q91933716 | Nectin-4 cis-interacts with ErbB2 and its trastuzumab-resistant splice variants, enhancing their activation and DNA synthesis |
| Q26764879 | Neoadjuvant therapy for early-stage breast cancer: the clinical utility of pertuzumab |
| Q37016382 | New developments in the treatment of HER2-positive breast cancer |
| Q34474239 | Next-generation cDNA screening for oncogene and resistance phenotypes |
| Q26745878 | Oligonucleotide-based systems: DNA, microRNAs, DNA/RNA aptamers |
| Q35414389 | Oncogenic HER2 fusions in gastric cancer |
| Q34363866 | Oncogenic HER2Δ16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors |
| Q38017732 | Overcoming treatment resistance in HER2-positive breast cancer: potential strategies. |
| Q52619388 | PAI-1 induces Src inhibitor resistance via CCL5 in HER2-positive breast cancer cells. |
| Q33737058 | Pathobiological implications of the d16HER2 splice variant for stemness and aggressiveness of HER2-positive breast cancer |
| Q64934294 | Personalized medicine in breast cancer: pharmacogenomics approaches. |
| Q49544395 | Predicting and Overcoming Chemotherapeutic Resistance in Breast Cancer |
| Q38786102 | Predictive biomarkers in the treatment of HER2-positive breast cancer: an ongoing challenge |
| Q33651583 | Prognostic and predictive biomarkers: tools in personalized oncology |
| Q39674995 | Quantitation of p95HER2 in Paraffin Sections by Using a p95-Specific Antibody and Correlation with Outcome in a Cohort of Trastuzumab-Treated Breast Cancer Patients |
| Q35643425 | Recent trends in antibody-based oncologic imaging |
| Q35591518 | Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications |
| Q37715501 | Resveratrol fuels HER2 and ERα-positive breast cancer behaving as proteasome inhibitor. |
| Q36544757 | Role of HER2 mutations in refractory metastatic breast cancers: targeted sequencing results in patients with refractory breast cancer |
| Q92025312 | Roles and mechanisms of alternative splicing in cancer - implications for care |
| Q26783076 | Roles for miRNAs in endocrine resistance in breast cancer |
| Q36791562 | SRSF3 and hnRNP H1 regulate a splicing hotspot of HER2 in breast cancer cells. |
| Q35222776 | Simultaneous Dual Selective Targeted Delivery of Two Covalent Gemcitabine Immunochemotherapeutics and Complementary Anti-Neoplastic Potency of [Se]-Methylselenocysteine |
| Q37690917 | Splice Variants of the RTK Family: Their Role in Tumour Progression and Response to Targeted Therapy |
| Q26798148 | Splicing Regulation: A Molecular Device to Enhance Cancer Cell Adaptation |
| Q35599629 | Targeting Bcl-2 in Herceptin-Resistant Breast Cancer Cell Lines |
| Q48234912 | Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3. |
| Q27025646 | Targeting Src family kinases in anti-cancer therapies: turning promise into triumph |
| Q34525673 | The ErbB2ΔEx16 splice variant is a major oncogenic driver in breast cancer that promotes a pro-metastatic tumor microenvironment |
| Q38302045 | The HER2 Signaling Network in Breast Cancer--Like a Spider in its Web. |
| Q36780754 | The HER2- and heregulin β1 (HRG)-inducible TNFR superfamily member Fn14 promotes HRG-driven breast cancer cell migration, invasion, and MMP9 expression |
| Q33894615 | The human splice variant Δ16HER2 induces rapid tumor onset in a reporter transgenic mouse. |
| Q64065309 | The landscape of d16HER2 splice variant expression across HER2-positive cancers |
| Q37046699 | Therapeutic siRNA for drug-resistant HER2-positive breast cancer. |
| Q38214802 | Therapeutic targeting of ERBB2 in breast cancer: understanding resistance in the laboratory and combating it in the clinic |
| Q91974174 | Towards personalized treatment for early stage HER2-positive breast cancer |
| Q34983690 | Unique expression features of cancer-type organic anion transporting polypeptide 1B3 mRNA expression in human colon and lung cancers |
| Q37707589 | mRNA expression of delta-HER2 and its clinicopathological correlation in HER2-overexpressing breast cancer |
Search more.